Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RANI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRani Therapeutics raises $20M through sale of 12.5M shares and 6.2M warrants at $1.07
Filed May 27, 2026 · Period ending May 26, 2026 · ~1 min read
Key Changes
-
high
Rani sold 12.5 million shares and pre-funded warrants for 6.2 million more shares to institutional investors at $1.07 each, raising ~$20M before fees. The warrants are immediately exercisable at $0.0001, functioning essentially as common stock.
Item 1.01 view on EDGAR → -
medium
Company agreed to 90-day restriction on issuing new shares and 9-month ban on variable rate transactions, protecting new investors from immediate dilution and preventing potentially harmful financing structures.
Item 1.01 view on EDGAR → -
medium
Directors, officers, and certain stockholders entered 60-day lock-up agreements preventing them from selling shares, signaling management confidence and preventing insider selling pressure immediately after the offering.
Item 1.01 view on EDGAR → -
low
Placement agents H.C. Wainwright and Chardan will receive 6% fee (~$1.2M) plus expenses, reducing net proceeds available to the company from the $20M gross raise.
Item 1.01 view on EDGAR →
Summary
Rani Therapeutics completed a $20 million capital raise by selling 12.5 million shares and pre-funded warrants for another 6.2 million shares to institutional investors at $1.07 per unit. The pre-funded warrants have a nominal exercise price of $0.0001 and are immediately exercisable, meaning they effectively represent additional common stock.
This represents significant dilution for existing shareholders—potentially up to 18.7 million new shares entering the market. The offering includes investor protections: a 90-day restriction on new share issuances and a 9-month ban on variable rate transactions, which prevents the company from pursuing more dilutive financing in the near term.
Management and insiders agreed to 60-day lock-ups, preventing them from selling into the new investor base. After deducting the 6% placement fee and expenses, Rani will net approximately $18.5-19 million. Retail investors should watch the company's cash burn rate and runway. The key question is whether this $20 million provides sufficient capital to reach meaningful clinical or regulatory milestones, or whether another dilutive raise will be needed within the next 12-18 months. Monitor upcoming quarterly filings for cash position and operating expense trends.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Rani Therapeutics executed securities purchase agreements for pre-funded warrants on May 26, 2026.
Added in current filing · verify on EDGAR →
Form of Securities Purchase Agreement, dated May 26, 2026
The company entered into securities purchase agreements on May 26, 2026, which included the issuance of pre-funded warrants. Pre-funded warrants are typically sold to investors at a price near the stock price minus a nominal exercise price, providing immediate capital while allowing investors to exercise warrants later. This represents a capital-raising transaction, though specific terms, amounts, and investor details are not disclosed in this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify